drugset / Trial / NCT03038295

a Prospective Cohort Study for Propranolol Treatment in Retinopathy of Prematurity

NCT03038295

Phase 2 Unknown 100 enrolled Guangdong Women and Children Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of oral/local propranolol in preterm newborns who diagnosed as early phase of retinopathy of prematurity (ROP).

Timeline

Start
2017-03
Primary completion
2018-12
Completion
2019-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule 6 ug Oral
Subject Propranolol Small molecule 0.2 % Oral
Subject Propranolol Small molecule 0.25 mg/kg Oral